Perspective Therapeutics (CATX) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Business overview and innovation

• Focuses on developing best-in-class radiopharmaceuticals with strong emphasis on pharmacokinetics and pharmacodynamics.

• Innovates new chemical entities using a range of isotopes, peptides, and linkers, aiming for clean drug compositions.

• Core expertise includes isotope delivery, manufacturing, and new compositions of matter.

Mechanism of action and differentiation

• Radiopharmaceuticals use a distinct, potent mechanism, delivering alpha or beta particles to destroy tumor cells.

• Alpha particles are highly effective, requiring fewer hits to kill cells and triggering immune responses.

• Drug design aims for rapid tumor targeting and minimal off-target organ exposure to reduce toxicity.

Clinical data and program updates

• Investigator-led study in India showed strong biochemical and anatomical responses in NET patients, including those with limited access to Western isotopes.

• U.S. phase I/II NET program targets radiopharmaceutical-naive patients, with ongoing data accrual and encouraging early results.

• University of Iowa data demonstrated safe, higher-dose administration tailored to kidney dose, with strong responses in post-lutetium patients.